WCN26-6228 Real-World Assessment of Nefecon as First-Line Therapy in IgA Nephropathy: Efficacy and Safety Outcomes

Read full text Summarise with VIRAT
Authors: Yixuan Zhao, Min Han
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Nefecon, the gut-targeted formulation of budesonide, designed to modulate gut-associated lymphoid tissue and suppress the synthesis of galactose-deficient IgA1, has shown significant efficacy in reducing proteinuria and preserving renal function in patients with IgA nephropathy (IgAN). However, real-world evidence regarding its efficacy and safety as an initial therapeutic option in the broader IgAN population remains limited.

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Chronic Kidney Disease and Diabetes Renal Transplantation Outcomes and Treatments

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104848–104848
Publication date
25 March 2026
Language
EN